Espa-Prazol 40mg 28 gastro-resistant tablets — Made in Germany — Free Delivery

Brand: Advanz Pharma
Product Code: Espa-Prazol
Availability: In Stock

$21.88

Add to Cart

Description

Product description

The preparation "Espa-Prazol®" is used for the following indications.

Adults and children over 12 years old: reflux esophagitis.

Adults:

eradication of Helicobacter pylori (H. pylori) in patients with H. pylori-associated gastric and duodenal ulcers in combination with appropriate antibiotics;
duodenal ulcer;
stomach ulcer;
Zollinger-Ellison syndrome and other hypersecretory pathological conditions.

Compound

Active ingredient: pantoprazole.

1 tablet contains 45.17 mg of pantoprazole sodium sesquihydrate (equivalent to 40.0 mg of pantoprazole).

Excipients: maltitol; sodium carbonate anhydrous; crospovidone (type B); sodium carmellose; calcium stearate.

Tablet shell: Opadry II Yellow 85G52042 (polyvinyl alcohol, talc, titanium dioxide (E 171), macrogol 3350, lecithin, iron oxide yellow (E 172)), sodium carbonate, methacrylic acid and ethyl acrylate copolymer (1: 1) dispersion 30% , triethyl acetate.

Contraindications

Hypersensitivity to the active substance, benzimidazole derivatives or any component of the preparation.

Method of administration and dosage

Espa-prazol®, gastro-resistant tablets, should be taken 1 hour before meals whole, do not chew or grind, drink with water.

Recommended dosage.

Adults and children over 12 years old.

Reflux esophagitis treatment.

The recommended dose is 1 tablet of Espa-Prazol® 40 mg per day. In some cases, the dose can be doubled (2 tablets of the preparation "Espa-Prazol®" 40 mg per day), especially if there is no effect from the use of other preparations for the treatment of reflux esophagitis. Reflux esophagitis usually takes 4 weeks to cure. If this is not enough, healing can be expected within the next 4 weeks.

Adults.

Eradication of H. pylori in combination with two antibiotics.

In patients with gastric and duodenal ulcers and who test positive for H. pylori, it is necessary to achieve eradication of the microorganism using combination therapy. Consideration should be given to local data on bacterial resistance and national recommendations for the use and administration of appropriate antibacterial agents. Depending on the sensitivity, the following therapeutic combinations can be prescribed for the eradication of H. pylori in adults:

1 tablet "Espa-Prazol®" 40 mg 2 times a day + 1000 mg of amoxicillin 2 times a day + 500 mg of clarithromycin 2 times a day;

1 tablet "Espa-Prazol®" 40 mg 2 times a day + 400-500 mg of metronidazole (or 500 mg of tinidazole) 2 times a day + 250-500 mg of clarithromycin 2 times a day;

1 tablet "Espa-prazol®" 40 mg 2 times a day + 1000 mg of amoxicillin 2 times a day + 400-500 mg of metronidazole (or 500 mg of tinidazole) 2 times a day.

When using combination therapy for the eradication of H. pylori, the second 40 mg Espa-Prazol® tablet should be taken in the evening 1 hour before meals. The duration of treatment is 7 days and can be extended for another 7 days. The duration of treatment is no more than two weeks. If further treatment with pantoprazole is indicated to ensure ulcer healing, dosing recommendations for gastric and duodenal ulcers should be considered. If combination therapy is not indicated, for example, in patients with a negative result for H. pylori, for monotherapy, the preparation "Espa-Prazol®" 40 mg is used in the following dosage.

Stomach ulcer treatment.

1 tablet "Espa-Prazol®" 40 mg per day. In some cases, the dose can be doubled (2 tablets of the preparation "Espa-Prazol" 40 mg per day), especially if there is no effect from the use of other preparations.

Stomach ulcers usually take 4 weeks to heal. If this is not enough, the ulcer can be expected to heal within the next 4 weeks.

Treatment of duodenal ulcers.

A duodenal ulcer usually takes 2 weeks to heal. If this is not enough, the ulcer can be expected to heal within the next 2 weeks.

Treatment of Zollinger-Ellison syndrome and other hypersecretory pathological conditions.

For long-term treatment of Zollinger-Ellison syndrome and other pathological hypersecretory conditions, the initial daily dose is 80 mg (2 tablets of the preparation "Espa-Prazol" 40 mg). If necessary, then the dose can be titrated, increasing or decreasing, depending on the indicators of gastric acidity. A dose exceeding 80 mg per day must be divided into two doses. A temporary increase in the dose to more than 160 mg of pantoprazole is possible, but the duration of use should be limited only by the period necessary for adequate control of acidity.

The duration of treatment for Zollinger-Ellison syndrome and other pathological conditions is not limited and depends on the clinical need.

Application features

Pregnant

The available data on the use of the preparation "Espa-prazol" in pregnant women (approximately 300-1000 reports of pregnancy results) indicate the absence of embryonic or feto / neonatal toxicity of the preparation. Reproductive toxicity has been observed in animal studies. As a precautionary measure, use of Espa-Prazol® in pregnant women should be avoided.

Lactation. Animal studies have shown the excretion of pantoprazole into breast milk. There are insufficient data on the excretion of pantoprazole into breast milk, but such excretion has been reported. Risk to newborns / babies cannot be ruled out. The decision to discontinue breastfeeding or to discontinue / withhold treatment with Espa-Prazol® should be made taking into account the benefits of breastfeeding for the baby and the benefits of treatment with Espa-Prazol® for the woman.

Fertility Pantoprazole has not impaired fertility in animal studies.

Children

"Espa-Prazol®" 40 mg is indicated for children over 12 years of age for the treatment of reflux esophagitis. The preparation is not recommended for use in children under 12 years of age, since the data on the safety and efficacy of the preparation for this age group are limited.

Drivers

Pantoprazole does not affect or has very little effect on the reaction rate when driving or using other mechanisms. It is necessary to take into account the possible development of adverse reactions, such as dizziness and visual disturbances (see section "Adverse reactions"). In such cases, you should not drive vehicles or work with other mechanisms.

Overdose

Overdose symptoms are unknown.

0 reviews

There are no reviews for this product.